The Estée Lauder Companies Announces Expanded Roles for Brian Franz and Amber English
9.9.2026 00:05:00 EEST | Business Wire | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced expanded leadership roles for two members of its Executive Team. Brian Franz has been appointed Chief Technology & Transformation Officer,expanding his responsibilities to include leading the company's enterprise-wide transformation. Amber English has been named President, Digital & Online, The Americas and Global Amazon Lead, assuming new enterprise-wide responsibility for The Estée Lauder Companies’ global relationship with Amazon. Both will continue to report directly to Stéphane de La Faverie, President and Chief Executive Officer, and remain members of The Estée Lauder Companies’ Executive Team. Both appointments are effective immediately.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908417554/en/
Brian Franz, Chief Technology & Transformation Officer, and Amber English, President, Digital & Online, The Americas and Global Amazon Lead
“Transformation at The Estée Lauder Companies is not a moment in time or a project with an end date. It’s a part of our strategy and is how we operate,” said de La Faverie. “Consumer expectations continue to rapidly evolve, and we must keep changing with them. Brian and Amber have each played important roles in advancing our consumer-centric transformation, using technology, digital commerce, and strategic partnerships to help our brands reach consumers in more relevant and differentiated ways. Their expanded responsibilities recognize the deep digital transformation underpinning the company’s next phase of growth and will help us move faster, strengthen our One ELC operating model, and continue building the capabilities needed for the future.”
Brian Franz: Technology as a Driving Force of Ongoing Transformation
In his expanded role, Franz will lead The Estée Lauder Companies’ ongoing, enterprise-wide transformation, bringing together initiatives focused on driving revenue and improving productivity, including the continued operationalization of the company’s Enterprise Business Services program. He will advance the company’s transformation agenda by accelerating AI-enabled processes, building critical technology skills across the organization, and driving next-generation ways of working. In addition to his new responsibilities, Franz will continue to oversee the Technology, Data & Analytics function globally, harnessing these capabilities to drive growth, efficiency, and ongoing transformation across the company.
Since joining the company in April 2025, Franz has advanced its strategic technology ecosystem, including a global partnership with Shopify to unify The Estée Lauder Companies’ omnichannel commerce foundation and support seamless consumer shopping experiences. He has also been instrumental in launching the company’s partnership with Accenture, which is simplifying shared services through greater standardization and scale. Together, these efforts demonstrate how technology can accelerate transformation across the enterprise.
“Over the past 18 months, we have focused on building the technology-driven foundations that will enable the company’s future and, with that, have embedded an expectation among our team for constant evolution and improvement,” said Franz. “How we work, make decisions, and ultimately serve our consumers will never be stagnant. Technology is one of the most powerful tools we have to make that evolution real, and I am excited to take on this expanded responsibility as we continue building a faster, simpler, and more connected company.”
Amber English: Advancing the Americas Digital Presence and Global Amazon Relationship
In her expanded role, English will lead and unify The Estée Lauder Companies’ global Amazon business, currently spanning 13 brands across 11 markets, to accelerate digital growth and create greater connectivity across markets. While continuing as President, Digital & Online, The Americas, she will oversee global consumer experience, creator commerce, cross-market sharing of best practices, and the company’s global partnership with Amazon.
English joined the company in December 2021 as Senior Vice President and General Manager, eCommerce, North America. She led the company’s entrance into Amazon Premium Beauty and TikTok Shop U.S. Since then, she has built the capabilities, expertise, and operating model to accelerate digital commerce across brand.coms, retailer.coms and social commerce in The Americas, building a scalable model that has become a blueprint for markets around the world. Her leadership in The Americas has helped drive the company’s broader global acceleration of digital commerce. In fiscal 2026, Online1 accounted for 34% of the company’s reported net sales, a three percentage point increase from fiscal 2025.
“Our work in The Americas has demonstrated what is possible when we combine strong brand building, differentiated consumer experiences, and the scale of digital commerce,” said English. “Amazon has been an exceptional partner, and this expanded global remit gives us the opportunity to scale what we’ve learned across markets while continuing to create differentiated experiences for consumers around the world.”
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary, NIOD, Avestan and Loopha, and Balmain Beauty.
ELC-C
| _________________________ |
1 Online sales include sales we make directly to our consumers through our brand.com sites and through third party platforms. It also includes estimated sales of our products through our retailers’ websites. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260908417554/en/
Contacts
Media Relations:
Brendan Riley
briley@estee.com
Investor Relations:
Rainey Mancini
rmancini@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom